For example, targeted therapies based on molecular targets such as BCR-ABL inhibitors in leukemia (16), BRAF and MEK inhibitors in melanoma (17, 18) and therapies targeting epidermal growth factor receptor (EGFR) in lung cancer and head-and-neck cancer patients (19) have significantly impacted the cancer treatment landscape. This evidence concerns the gene EGFR and lung carcinoma.